Atreca, Inc. (NASDAQ:BCEL – Get Rating) CEO John A. Orwin sold 20,908 shares of the company’s stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $1.78, for a total transaction of $37,216.24. Following the transaction, the chief executive officer now owns 100,492 shares in the company, valued at $178,875.76. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Atreca Trading Down 6.7 %
Shares of NASDAQ:BCEL opened at $1.68 on Friday. The company has a market capitalization of $63.44 million, a price-to-earnings ratio of -0.58 and a beta of 0.69. Atreca, Inc. has a 12 month low of $1.51 and a 12 month high of $7.00. The firm’s 50-day moving average is $2.08 and its 200 day moving average is $2.24.
Atreca (NASDAQ:BCEL – Get Rating) last issued its earnings results on Monday, August 8th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.02). As a group, equities analysts forecast that Atreca, Inc. will post -2.71 EPS for the current fiscal year.
Institutional Investors Weigh In On Atreca
Analyst Upgrades and Downgrades
Separately, Brookline Capital Management reiterated a “buy” rating on shares of Atreca in a report on Monday, August 8th.
Atreca, Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
- Get a free copy of the StockNews.com research report on Atreca (BCEL)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.